Abivax SA announces first patient enrolled in ENHANCE-CD Phase 2b trial (10.28 -0.10)
- Co announces the first patient was enrolled in its Phase 2b ENHANCE-CD trial evaluating obefazimod in patients with Crohn's disease.
- "The enrollment of the first patient in our Phase 2b trial marks a significant step forward in meeting the need for a convenient, oral, once-daily treatment option for people with moderately to severely active Crohn's disease. This milestone brings us closer to addressing the unmet needs of patients seeking effective therapies with fewer burdens on their daily lives."